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TrkB is a high afﬁnity receptor for the brain derived neurotrophic
factor (BDNF) and its phosphorylation stimulates activation of
several intracellular signalling pathways linked to cellular growth,
differentiation and maintenance. Identiﬁcation of various activa-
tors and inhibitors of the TrkB receptor and greater understanding
their binding mechanisms is critical to elucidate the biochemical
and pharmacological pathways and analyse various protein crys-
tallization studies. The data presented here is related to the
research article entitled “Brain Derived neurotrophic factor is
involved in the regulation of glycogen synthase kinase 3β (GSK3β)
signalling” [1]. Cyclotraxin B (CTXB) is a disulphide bridge linked
cyclic peptide molecule that interacts with TrkB receptor and
inhibits the BDNF/TrkB downstream signalling. This article reports
for the ﬁrst time binding mechanism and interaction parameters of
CTXB with the TrkB receptor. The molecular model of CTXB has
been generated and it’s docking with TrkB domain carried out to
determine the critical residues involved in the protein peptide
interaction.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
. Chitranshi), vivek.gupta@mq.edu.au (V. Gupta).
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Value of the data
 Three dimensional molecular model of the cyclic peptide cyclotraxin B was generated for the ﬁrst
time to determine its interactions with the TrkB receptor.
 Future studies to determine pharmacological, biochemical or interaction studies of TrkB receptor or
related molecules will be facilitated by the interaction and binding parameters reported here.
 Binding interactions of CTXB with TrkB will determine its potential usage in pharmacological
studies and development of new derivatives and ligands.1. Data
The data shown here elucidates molecular modeling of cyclic peptide cyclotraxin B which is a TrkB
inhibitor. Active site of the extracellular D5 domain of the TrkB receptor which is primarily involved in
this interaction was also modelled. Finally the cyclic peptide inhibitor was also identiﬁed and docking
carried out with the extracellular D5 domain of TrkB. The interacting amino acid residues that are
involved in docking are identiﬁed and various interaction parameters provided in detail using a
combination of molecular modeling and molecular docking computational tools.2. Experimental design, materials and methods
2.1. Selection and preparation of cyclotraxin B, TrkB inhibitor
Cyclotraxin B (CTXB) is a cyclic peptide chain of 10 amino acid linked by a disulphide bridge [2]. It
is an inhibitor of the TrkB receptor activation and its downstream signalling pathway mediated by
BDNF binding [1,3–5]. Cyclization is important to provide stability to the peptide macromolecule. The
primary structure of the peptide is known and in this manuscript we report for the ﬁrst time the
putative three dimensional structure of the peptide (Fig. 1A). The two dimensional (2D) and three
dimensional (3D) structure of the CTXB was built using ChemDraw Ultra 8.0 (Cambridgesoft, Wal-
tham, MA, USA) (Fig. 1B and C). Extensive energy minimization was performed using the Austin
Model-1 (AM1) programme until the root mean square (RMS) gradient value became smaller than 0.
100 kcal/mol Å. The molecule was further subjected to re-optimization via MOPAC (Molecular Orbital
Package) method [6] until the RMS gradient attained a value lesser than 0.0001 kcal/mol Å. The
chemical properties of CTXB was calculated by ACD (Advanced Chemistry Development, Canada) labs
Chemsketch software and the data is presented in Table 1 [7].
2.2. Molecular modeling and generation of TrkB binding region
The primary structure of TrkB receptor and its various domains were examined [8]. Crystal
structure of the extracellular D5 domain of the TrkB which exhibits binding with the human
Table 1
The chemical property and the calculation of cyclotraxin B (CTXB) as evaluated using ACD labs Chemsketch software.
Chemical properties Calculations
Molecular formula C48H73N13O17S3
Formula weight 1200.36512
Composition C(48.03%) H(6.13%) N(15.17%) O(22.66%) S(8.01%)
Molar refractivity 296.2570.4 cm3
Molar volume 805.875.0 cm3
Parachor 2467.976.0 cm3
Index of refraction 1.65670.03
Surface tension 87.975.0 dyne/cm
Density 1.4870.1 g/cm3
Dielectric constant Not available
Polarizability 117.4470.5 10-24 cm3
Monoisotopic mass 1199.440948 Da
Nominal mass 1199 Da
Average mass 1200.3651 Da
Fig. 1. Cyclotraxin B stuructre (A) one dimensional, (B) two dimensional and (C) three dimensional view.
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asymmetric unit of the crystal structure contains a single copy of the TrkB-D5:NT-4/5 complex,
comprising one homodimer of NT-4/5 bound to two monomers of TrkB-D5. The two monomer chain
of TrkB-D5 (chains X and Y) are identical. These chains are known to interact with the BDNF/ NT-4/5
protein. Only chain X of PDB id 1HCF was considered in the present study for its potential interactions
with the CTXB that highlights the location of the conserved interaction site. The optimization of
proteins was carried out using well characterized UCSF Chimera software (San Francisco, California,
USA), implying amber parameters, followed by minimization with MMTK (Molecular Modeling
Toolkit) method. The steepest minimizations was ﬁrst performed in 1000 steps to relieve highly
unfavourable clashes than followed by conjugate gradient minimization in 500 steps with a step size
of 0.02 Å for more effective reaching an energy minimum [10, 11].
Fig. 2. Predicted binding sites of CTXB peptide ‘‘CNPMGYTKEG’’ core motif on the surface of TrkB-D5 domain as predicted by
the PEPSITE2 programme. The six ball shaped structures indicate the predicted locations of six residues from ‘‘CNPMGYTKEG’’.
(1–8) distribution of 6 amino acids of the peptide predicted on the surface of TrkB-D5 in the sequence of Cys (C), Asn (N), Pro
(P), Met (M), Tyr (Y) and Lys (K) (labelled) and (9–10) distribution of 6 selected amino acids of CTXB binding to TrkB-D5-Pro (P),
Met (M), Gly (G), Tyr (Y), Thr (T) and Lys (K) (labelled).
Table 2
PepSite2 binding score prediction of selected cyclotraxin B (CTXB) residue sequences to the TrkB-
D5 domain.
Rank Peptide sequence order Pepsite2 score
1 CNPMYK 0.02733
2 CNPMYK 0.03015
3 CNPMYK 0.03266
4 CNPMYK 0.03583
5 CNPMYK 0.03719
6 CNPMYK 0.04098
7 CNPMYK 0.04435
8 CNPMYK 0.04993
9 PMGYTK 0.05985
10 PMGYTK 0.06992
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The protein motif was subjected to in silico assessment of the potential binding of selected CTXB
residues to different regions on the TrkB D5 surfaces. This binding interactions were assessed in terms
of probability of CTXB participating residues binding to the TrkB D5 receptor surface and theoretical
scores determined using the PepSite2 server [12]. Peptide binding may also affect the tyrosine
phosphorylation proﬁle [13] of the TrkB receptor translating into its altered activity which can be
assessed in future investigations. Surface accessibility of the ligand to various binding pockets was
also examined [14].
PepSite2 is a computational tool that scans the surface of a given protein for patches or grooves
that are likely to inﬂuence binding of individual amino acid residues or peptides up to ten amino acids
and provides a score that reﬂects the propensity of the peptide to bind to that region. The PepSite
score is expressed in relative units and the higher scores reﬂects superior binding. We applied PepSite
in a sliding window of 10 residues to assess the binding of the TrkB-D5 domain and CTXB peptide
sequence (CNPMGYTKEG). The scores of the CTXB binding to different regions of TrkB D5 domain are
presented (Fig. 2A, Model 1, Table 2) [1].
Table 3
The top 20 docking scores and geometrical parameters of the peptide CTXB with TrkB-D5 domain; ACE: Atomic Contact Energy.
Rank Score Area ACE Transformation
1 5538 652.1 344.82 0.57 1.01 2.62 10.48 3.78 29.57
2 5282 597.6 272.85 1.01 0.26 0.32 12.66 4.68 28.84
3 5100 620 330.86 –1.52 0.07 0.81 –11.83 –7.13 27.44
4 4966 528.9 126.23 –0.31 –0.63 –2.16 –22.34 8.83 21.59
5 4878 623.4 300.47 2.71 0.78 1.27 13.25 4.12 29.20
6 4824 571.7 214.66 –0.11 1.20 2.50 –5.75 11.23 7.03
7 4800 621.7 217.57 –2.59 –0.46 0.54 –22.14 6.07 23.60
8 4678 531.9 182.76 0.67 0.16 1.87 20.33 9.72 23.42
9 4654 512.8 234.35 0.84 0.57 0.51 12.13 2.05 31.89
10 4642 570.9 250.43 1.34 0.11 1.76 23.69 10.32 20.31
11 4606 539.9 170.59 0.32 1.01 2.51 22.65 10.28 21.86
12 4536 521.6 189.48 3.07 0.42 0.56 20.13 9.32 24.74
13 4530 735.8 436.61 0.46 1.21 2.78 3.58 11.15 12.99
14 4522 622 273.37 1.99 0.45 2.81 8.24 1.98 30.78
15 4358 547.6 276.07 0.05 0.96 2.97 7.11 6.08 31.48
16 4264 468.6 196.84 2.26 –0.23 2.23 –1.86 14.82 14.52
17 4242 531.7 154.98 0.67 –0.38 2.13 16.81 14.23 21.56
18 4240 548.7 304.69 0.50 0.35 0.24 6.28 11.67 5.72
19 4234 458.8 155.03 2.26 0.60 2.85 2.98 13.89 13.16
20 4230 653.7 351.22 0.76 1.23 2.83 5.51 13.82 10.66
Fig. 3. Interacting residues and binding mode of CTXB with TrkB-D5 domain (A) Docking of TrkB (ribbon structure) with the
CTXB (stick model) showing critical residues (rank 1) involved in interaction, (B) enlarged view of the interaction pocket within
5.5 Å region around the ligand, CTXB-TrkB-D5 complex and (C) surface view showing the grove in TrkB-D5 domain (Cyan)
locating CTXB peptide (pink). Green dashed line denotes the hydrogen bonding and brown dashed line reﬂects pi-sulpha
interactions and stacking. The images were generated with the Discovery Studio 4.0 Client (Accelrys, Inc., San Diego, CA, USA).
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The protein-peptide docking was performed with the PatchDock software available in the public
domain [15]. The crystal structure of TrkB (PDB ID: 1HCF) was retrieved from Protein Data Bank. The
single chain of TrkB-D5 as described previously was used for docking study under default complex-
type settings. Molecular visualization and general analysis were done using the program PyMOL and
Discovery Studio 4.0 softwares [16]. TrkB residues closer than 5.5 Å to any of the C-terminal NT-4/5
amino acids (Cys345-Asn350) were selected for docking (Fig. S1). The docking scores, atomic contact
energies and geometrical parameters are compiled as Table 3. The hydrogen bond between TrkB-D5
and CTXB (rank 1) was observed to be formed between the amino acid residues His353, Met354,
Ala376, His377 and Trp381 (Fig. 3A). The pi-sulpha interaction was also observed between CTXB and
Met354 (Fig. 3B). Surface binding of CTXB with TrkB-D5 domain is shown in Fig. 3C. The selected
binding pocket of TrkB-D5 was observed to overlap with the C-terminal region of the NT-4/5 binding
site (Fig. S2). The two dimensional (2D) interaction map was created by LigPlotþ which helped to
identify new interacting residues in the TrKB-D5:CTXB complex [17]. Ser294, Asn320, Gln373 and
Ser375 of TrkB-D5 were identiﬁed to form hydrogen bonds with CTXB. Trp381 was observed to be
involved in CTXB TrkBD5 binding using both the Discovery Studio 4.0 as well as the LigPlotþ pro-
grammes (Fig. S3).Acknowledgements
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